Abstract
Twenty-seven women with disseminated estrogen receptor-negative breast cancer received an aggressive chemotherapy program of prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide. Responses were achieved in 21 of 26 (81%) evaluable patients, eight (31%) of whom had complete responses. The median survival was 17 months. Despite the favorable overall response and a significant number of complete responses, all patients eventually relapsed. Although most patients relapsed systematically, two relapsed initially in the CNS.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / analysis
-
Breast Neoplasms / drug therapy*
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Drug Administration Schedule
-
Female
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use
-
Humans
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Middle Aged
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Receptors, Estrogen / analysis*
Substances
-
Receptors, Estrogen
-
Doxorubicin
-
Cyclophosphamide
-
Fluorouracil
-
Prednisone
-
Methotrexate